Drug Substance Manufacturing Optimized

Leverage our technologies, scale, and unique experience

Emergent_manufacturing_drug_substance-1

Emergent Platforms & Technologies

Your science and our technology platforms can make for a very powerful combination for your drug substance. Whether you’re pursuing the potential offered by next-gen therapies or leveraging the track record of traditional approaches, you’ll find the right people, processes, equipment, and technologies at Emergent CDMO to accelerate and optimize your drug substance manufacturing program.

Emergent_CDMO_carmine_icons_mammalian_small

MAMMALIAN

Flexible, scalable cGMP manufacturing of recombinant proteins and monoclonal antibodies from a variety of mammalian cell lines.

Emergent_CDMO_carmine_icons_plasma_small_plasma copie

Plasma Protein

Decades of experience isolating therapeutic proteins (immunoglobulins) under cGMP conditions from mammalian plasma.

Emergent_CDMO_carmine_icons_gene_theraphy_small_dna copie

Next-Gen Therapies

Your partner in realizing the potential of game-changing therapeutics.

Technologies Scale Downstream Processing

Emergent_CDMO_carmine_icons_mammalian_small  Mammalian

 

  • Single-use bioreactors 
    • 50L
    • 200L
    • 500 / 750L 
    • 2000L
    • 4000L
  • Centrifugation
  • Chromatography
  • Filtration
  • UF/DF

Emergent_CDMO_carmine_icons_plasma_small_plasma copie  Plasma Protein

 

  • 240L stainless steel pooling tankage
  • 480L stainless steel pooling tankage
  • 1000L human hyperimmune
  • 1000L equine hyperimmune
  • 1800L working volume
  • Up to three segregated viral zones
  • Chromatography
  • Filtration
  • UF/DF

Let’s Start A Conversation

Connect now